Ingabe Ukwelashwa Kwama-Antibiotic Kuphumelela I-Rheumatoid Arthritis?
Umlando Wokusesha Imbangela neCure
Njengoba kungelakho ukwelashwa okwaziwa ngezinhlobo ezingaphezu kuka-100 ze- arthritis , ukwelashwa nokubhekana nezibonakaliso ezibuhlungu kuye kwaba yimbangela yokukhathalela iziguli kanye nodokotela. Ngawo-1930, imbangela yebhaktheriya ye- arthritis ye- rheumatoid yaphenywa, kodwa ucwaningo lwaluhlala isikhathi esifushane ngaphandle kwamacala ahlukene a- arthritis ahlaselayo noma aphethwe yi- septic .
Ngo-1939, ukuhola kwangempela ngokuqondene nesifo esithathelwanayo se-rheumatoid arthritis kwavela lapho i-mycoplasma, i-atypical bacteria-like bacteria, ihlukaniswa nezidakamizwa ze-rheumatic. Abaphenyi babesevele babonise ukuthi ama-mycoplasma abangela i-arthritis kumagundane, amagundane, izinkukhu, izimbuzi, nezinkomo. Babethole ama-mycoplasmas emapheshana we-genitourinary abantu, ikakhulukazi abesifazane.
Ngo-1949 ku-International Congress kwi-Rheumatic Diseases ubuhlobo obukhona phakathi kwama-mycoplasmas nezifo ezihlangene kwabikwa. Ngemuva kokuthola izibonelelo zokucwaninga zeNational Institutes of Health (NIH) ngo-1950, uThomas McPherson Brown, MD kanye nozakwabo e-unit of research arthritis babika ngonyaka olandelayo ukuthi indlela yokugula yesifo sofuba yayinomzimba omkhulu we-antigen ne-antibody ( ne-mycoplasma njenge-antigen okusolakala) kunokuba uhlobo olubhebhethekisa futhi oludluliselwayo.
Ngo-1955, i-unit yokucwaninga ibike ukuthi ama-mycoplasmas, ngokungafani nama-bacterium kanye nama-virus angaphila emasikini angama-cell ngaphandle kokubhubhisa amangqamuzana omzimba. Ukuqhubeka nokusekela i-mycoplasmas njenge-agent causative / antigen, ngo-1964 isifo esiphakeme sama-antibodies e-blood of rheumatoid arthritis kanye neziguli ze- lupus zitholakale, kubonisa ukutheleleka kwamanje noma kwangaphambilini.
Futhi kwaqaphela ukuthi kwakukhona izigameko ezingaphezulu kwezingu-4: 1 ze-mycoplasma antibodies ezinesifazane ezibonisa ukulungiswa nezimo eziphakeme ze-arthritis ye-rheumatoid yabesifazane.
I-Antibiotic Therapy
Imizamo yokukhombisa ukuthi ukusebenza kwe-tetracycline yokwelapha kwaqala ukusebenza futhi kubikwa kuqala eminyakeni engaphezu kwengu-40 eyedlule nguThomas McPherson Brown, MD. Ngemva kwamasonto amabili ngemuva kokushona kukaBrown ngo-1989, i-NIH yacela izicelo zokunikezwa kwezivivinyo ezilawulwayo zokwelapha nge-tetracycline therapy ngenxa ye-rheumatoid arthritis ayeyifunayo. Imiphumela yokuqala yokuhlolwa kwezifo zokwelapha, okwaziwa manje ngokuthi i-MIRA noma i-Minocycline ku-Rheumatoid Arthritis, yayithembise futhi i-NIH icele izicelo zokunikezwa kwezifundo ze-mycoplasma nezinye izifo ezithathelwanayo njengezimbangela zezifo zethuthroid ngo-1993, kanye nesifundo sezindiza zokulwa nama-antibiotic isifo samathambo ngonyaka ka-1994.
Umphumela we-MIRA trial trial, wathi, "Iziguli ezihlushwa yi-RA emincane kuya ezilinganiselwe manje zinokukhetha omunye ummeli wezokwelapha. Akukhona nje ukuthi imithi elwa namagciwane yayinciphisa kakhulu izimpawu, kodwa imiphumela emibi yayincane kakhulu futhi ingaphansi kakhulu kunokuba ibonwe kwezinye izinto ezivamile izifo zokwelapha. "
"Kungani I-Arthritis?"
Kuyo yonke le minyaka, imibono egxila ku-mycoplasma njenge-ejenti ephathekayo ethintekayo kanye ne-tetracycline njengoba ukwelashwa kwama-antibiotic okhethweni kuye kwaphazamiseka ngenxa yokungabi nemali eyanele yokwenza ucwaningo olunzulu nakwezombusazwe.
"Kungani I-Arthritis?" nguHarold W. Clark, Ph.D., omunye wabalingani bakaBrown, uhlola izifo zesifo sofuba, amashumi eminyaka yocwaningo, ukufuna ukwelashwa, nokukhungatheka kwabacwaningi abanobugebengu obuphikisana ne-anti-mycoplasma bekunganakwa iminyaka engu-40 uhulumeni nezinhlangano ezihlukahlukene ze-arthritis. UClark ukholelwa ukuthi imizamo yayinqanyuliwe ngoba ukwelashwa okuphephile, okulula kusongela ukwakhiwa kwezokwelapha njengoba iziguli zingafuna ukungenelela ngokwezempilo.
Odokotela abaningi bahlala bengabazeki kanti namanje abakhombisi ukwelashwa kwama-antibiotic iziguli zabo. I-Arthritis Foundation ibonakala ingacabangi ngisho nangemva kokulashwa kwama-antibiotic kwakubhekwa njengokuphephile nokuphumelelayo.
Umqondisi wezokwelapha esekelwe kuthiwa akazange abheke ukwelashwa njengendlela yokufunda nokufunda kabanzi mayelana nemingcele kanye nokusetshenziswa kwesikhathi eside kwe-minocycline kwakudingeka.
Ngokusho kwe-American College of Rheumatology, "i-Minocycline inqunyelwe iziguli ezinezimpawu zesifo samathambo esifubhekile. Ngezinye izikhathi kuhlangene neminye imithi yokwelapha iziguli ezinezimpawu eziqhubekayo zalolu hlobo lwe-arthritis."
Imithombo:
Kungani I-Arthritis? Ukufuna Imbangela Nokwelashwa Kwe-Arthritis Ye-Rheumatoid, nguHarold W. Clark, Ph.D., 1997
Cannon, Michael. I-Minocycline (i-Minocin). I-American College of Rheumatology. Kubuyekezwe ngoMashi 2015.